Laurus Labs
- Market Cap
- ₹1,23,980 Cr
- P/E
- 92.52
Key Fundamentals
LargecapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 17.80%
- Debt to Equity
- 0.43
- EPS (TTM)
- ₹24.80
- Book Value
- ₹112.18
- Market Cap
- ₹1,23,980 Cr
- P/E (TTM)
- 92.52
- P/B
- 20.45
- ROE
- 18.30%
- Dividend Yield
- 0.04%
- EBITDA
- ₹1,833 Cr
- 52W High
- ₹2,488.00
- 52W Low
- ₹917.95
- Day Range
- ₹2,286.80 – ₹2,320.00
- Volume
- 8,79,357
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 66
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 23
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 70
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 48
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 95
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 51
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 19.0%
Weaknesses
4- Stock is trading at 20.5 times its book value
- The company has delivered a poor sales growth of 7.19% over past five years.
- Company has a low return on equity of 10.4% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 5 | 6 | 8 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bullish | 3 | 0 | 7 |
Oscillators
Bearish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 53.53
- Neutral
- MACD (12,26,9)
- 62.40
- Bearish
- SMA (50)
- 2,126.17
- Bullish
- SMA (200)
- 1,547.69
- Bullish
As of
Analyst Rating
6 of 12 analysts rate Buy, 3 Hold, 3 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +14.38% |
|---|---|
| 5Y | +7.19% |
| 3Y | +4.09% |
| 1Y | +22.67% |
| TTM | +23.03% |
Net profit
| 10Y | +20.84% |
|---|---|
| 5Y | −1.99% |
| 3Y | +3.92% |
| 1Y | +148.60% |
| TTM | +95.31% |
Operating cash flow
| 10Y | +24.47% |
|---|---|
| 5Y | +17.25% |
| 3Y | +17.78% |
| 1Y | +169.77% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +5.84 pp |
|---|---|
| 5Y | −6.04 pp |
| 3Y | −0.15 pp |
| 1Y | +7.20 pp |
| TTM | +6.98 pp |
Revenue by year
| Mar 2017 | ₹1,905 Cr |
|---|---|
| Mar 2018 | ₹2,056 Cr |
| Mar 2019 | ₹2,292 Cr |
| Mar 2020 | ₹2,832 Cr |
| Mar 2021 | ₹4,814 Cr |
| Mar 2022 | ₹4,936 Cr |
| Mar 2023 | ₹6,041 Cr |
| Mar 2024 | ₹5,041 Cr |
| Mar 2025 | ₹5,554 Cr |
| Mar 2026 | ₹6,813 Cr |
Net profit by year
| Mar 2017 | ₹190 Cr |
|---|---|
| Mar 2018 | ₹168 Cr |
| Mar 2019 | ₹94.00 Cr |
| Mar 2020 | ₹255 Cr |
| Mar 2021 | ₹984 Cr |
| Mar 2022 | ₹832 Cr |
| Mar 2023 | ₹793 Cr |
| Mar 2024 | ₹162 Cr |
| Mar 2025 | ₹358 Cr |
| Mar 2026 | ₹890 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Laurus Labs trades at ₹2,338 as of 2026-11-17 with a market cap of ₹1,26,325 crore and a trailing P/E of 94.27x. The stock has surged 117% over the past year, supported by a sharp TTM profit growth of 96%, but longer-term profit compounding over five years remains negative at -2%, highlighting the cyclical nature of recent earnings recovery.
- TTM profit growth of 96% signals a strong earnings recovery, indicating a potential inflection in the business cycle
- TTM sales growth of 23% shows meaningful top-line acceleration compared to the 3-year compounded sales growth of just 4%
- 10-year compounded profit growth of 21% demonstrates a long track record of earnings expansion through cycles
- ROE has improved to 16.38% currently and 18% last year, up from a 3-year average of 10%, reflecting improving capital efficiency
- ROCE of 19.67% indicates healthy returns on total capital employed, suggesting productive deployment of both equity and debt
- Debt-to-equity ratio of 0.46 is manageable for a capital-intensive healthcare company, providing financial flexibility for growth investments
- 10-year compounded sales growth of 14% reflects a sustained ability to scale revenues over the long term
- The company has maintained a healthy dividend payout ratio of 19.0%, returning capital to shareholders even through periods of earnings volatility
- Trailing P/E of 94.27x is extremely elevated, demanding sustained high earnings growth to justify the valuation
- Price-to-book ratio of 20.84x is exceptionally rich, meaning the stock trades at nearly 20 times its book value
- 5-year compounded profit growth is negative at -2%, indicating that the recent TTM surge follows a prolonged earnings decline rather than steady compounding
- 5-year compounded sales growth of only 7% is modest for a company commanding such premium valuation multiples
- 3-year average ROE of only 10% suggests that the recent improvement to 16-18% may not be structurally sustainable
- Dividend yield of just 0.05% offers negligible income return, placing nearly all return expectations on capital appreciation
- There are indications the company might be capitalizing interest costs, which could overstate reported profitability and asset values
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Laurus Labs delivered a standout Q2 FY27 with 126% profit growth and 75% CDMO revenue surge, supported by margin expansion to 34.5% and rising FPI interest. However, the CEO selling 95% of his direct holding near the all-time high of ₹2,488 triggered a sharp 9% single-day correction and raised alignment concerns, despite core promoter holding via NSN Holdings (~23%) remaining intact. Valuations remain stretched at ~98x trailing PE. Near-term trajectory hinges on whether Q3 results sustain the CDMO momentum and whether management provides clarity on the promoter sales to restore market confidence.
- Promoters sell ₹500cr near peak Nov 16
CEO Satyanarayana Chava sold 14.85 lakh shares (95% of direct holding) and Leven Holdings sold 4.78 lakh shares on Nov 11 when the stock hit its record high of ₹2,488. Total promoter sale exceeded 20 lakh shares worth ~₹500 crore.
- Stock crashes 9% on insider sale Nov 16
Shares fell ~9% to ₹2,205 on Nov 16, the worst single-day drop in nearly two years, as delayed disclosure of the Nov 11 promoter sales hit the market in one shock.
- Stretched valuation at ~98x PE Nov 16
Trailing P/E ratio hovered around 98x, nearly 3x the industry average, leaving little room for negative surprises after a 130% one-year rally.
- Record Q2 with 126% profit surge Nov 16
Q2 FY27 consolidated net profit jumped 126% YoY to ₹441 crore on revenue of ₹2,206 crore (+33% YoY). EBITDA rose 78% to ₹762 crore with margins expanding 850bps to 34.5%.
- CDMO revenue surges 75% Nov 16
CDMO segment revenue grew 75% YoY to ₹904 crore in Q2 FY27, with small-molecule CDMO alone up 86% to ₹875 crore. Analysts forecast CDMO revenue to reach ₹7,160 crore by FY29E.
- Pharma sector leader, up 112% YTD Nov 5
Laurus Labs led the pharma sector with a 112% YTD gain as the pharma index rose 27%, significantly outperforming other sectors. The stock rallied 171% in nine months from its Feb low of ₹918.
- Investor conference participation Nov 10
Laurus Labs confirmed participation in an annual investor conference in Mumbai on Nov 17, 2026, with no price-sensitive information to be shared.
- Joint Company Secretary appointed Oct 29
Kundan Kumar Jha appointed as Joint Company Secretary effective Nov 1, 2026, bringing over 23 years of corporate governance experience.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 | 2,206 |
| Expenses | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 | 1,456 |
| Operating Profit | 188 | 181 | 241 | 171 | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 | 750 |
| OPM % | 15% | 15% | 17% | 14% | 15% | 20% | 24% | 24% | 24% | 27% | 28% | 32% | 34% |
| Other Income | 2 | 2 | 19 | 3 | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 | 13 |
| Interest | 42 | 51 | 50 | 49 | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 | 44 |
| Depreciation | 93 | 98 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 | 127 |
| PBT | 54 | 35 | 107 | 18 | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 | 592 |
| Tax % | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% | 26% |
| Net Profit | 37 | 23 | 75 | 13 | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 | 436 |
| EPS (₹) | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.66 | 5.17 | 6.80 | 8.17 |
| YoY Sales growth | −22 | −23 | 4 | 1 | 0 | 18 | 19 | 31 | 35 | 26 | 5 | 29 | 33 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,327 | 1,778 | 1,905 | 2,056 | 2,292 | 2,832 | 4,814 | 4,936 | 6,041 | 5,041 | 5,554 | 6,813 | 7,823 |
| Expenses | 1,126 | 1,415 | 1,497 | 1,642 | 1,935 | 2,266 | 3,262 | 3,512 | 4,448 | 4,261 | 4,499 | 5,028 | 5,442 |
| Operating Profit | 200 | 362 | 408 | 414 | 357 | 565 | 1,552 | 1,424 | 1,592 | 779 | 1,055 | 1,785 | 2,381 |
| OPM % | 15% | 20% | 21% | 20% | 16% | 20% | 32% | 29% | 26% | 15% | 19% | 26% | 30% |
| Other Income | 34 | 4 | 32 | 29 | 16.15 | 5.92 | 23.66 | 14 | 6 | 26.34 | 75 | 47 | 40 |
| Interest | 106 | 111 | 100 | 80 | 88 | 90 | 68 | 102 | 165 | 183 | 216 | 171 | 166 |
| Depreciation | 62 | 86 | 106 | 125 | 164 | 187 | 205 | 251 | 324 | 385 | 430 | 480 | 494 |
| PBT | 67 | 169 | 234 | 237 | 120 | 294 | 1,301 | 1,084 | 1,109 | 236 | 484 | 1,182 | 1,761 |
| Tax % | −2% | 21% | 19% | 29% | 22% | 13% | 24% | 23% | 28% | 29% | 27% | 25% | — |
| Net Profit | 68 | 134 | 190 | 168 | 94 | 255 | 984 | 832 | 793 | 162 | 358 | 890 | 1,332 |
| EPS (₹) | 1.38 | 2.71 | 3.60 | 3.16 | 1.76 | 4.77 | 18.33 | 15.40 | 14.67 | 2.98 | 6.64 | 16.46 | 24.80 |
| Div. Payout % | 0% | 2% | 8% | 9% | 17% | 10% | 11% | 13% | 14% | 27% | 18% | 12% | — |
| Sales growth | 14 | 34 | 7 | 8 | 11 | 24 | 70 | 3 | 22 | −17 | 10 | 23 | 23 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 | 108 | 108 |
| Reserves | 640 | 774 | 1,225 | 1,377 | 1,452 | 1,663 | 2,490 | 3,244 | 3,930 | 4,003 | 4,365 | 5,192 | 5,953 |
| Borrowings | 888 | 1,094 | 842 | 980 | 1,036 | 1,079 | 1,482 | 1,777 | 2,015 | 2,577 | 2,764 | 2,518 | 2,625 |
| Other Liabilities | 345 | 339 | 481 | 554 | 737 | 901 | 1,671 | 1,840 | 1,608 | 1,699 | 2,099 | 2,693 | 2,828 |
| Total Liabilities | 1,888 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 | 10,511 | 11,514 |
| Fixed Assets | 801 | 1,021 | 1,230 | 1,481 | 1,629 | 1,726 | 2,171 | 2,652 | 3,409 | 3,890 | 4,123 | 4,371 | 4,351 |
| CWIP | 110 | 70 | 143 | 163 | 110 | 67 | 362 | 813 | 551 | 423 | 458 | 773 | 1,282 |
| Investments | 7 | 7 | 3 | 3 | 3 | 3 | 3 | 31 | 50 | 124 | 233 | 309 | 310 |
| Other Assets | 970 | 1,126 | 1,277 | 1,369 | 1,589 | 1,953 | 3,214 | 3,472 | 3,651 | 3,950 | 4,521 | 5,058 | 5,570 |
| Total Assets | 1,888 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 | 10,511 | 11,514 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −65 | 182 | 332 | 342 | 298 | 347 | 733 | 911 | 994 | 666 | 602 | 1,624 |
| Investing | −397 | −312 | −289 | −384 | −253 | −221 | −941 | −914 | −997 | −822 | −680 | −1,086 |
| Financing | 486 | 103 | −54 | 42 | −45 | −128 | 255 | 30 | −27 | 250 | 39 | −525 |
| Net Cash Flow | 24 | −27 | −10 | 1 | 0 | −1 | 47 | 27 | −30 | 93 | −39 | 13 |
| Free Cash Flow | −447 | −144 | 55 | −49 | 44 | 125 | 49 | 34 | 6 | −10 | 61 | 560 |
| CFO/EBITDA | −24 | 59 | 94 | 98 | 91 | 68 | 62 | 77 | 80 | 99 | 70 | 107 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 78 | 91 | 109 | 101 | 113 | 102 | 99 | 100 | 96 | 120 | 132 | 115 |
| Inventory Days | 210 | 176 | 186 | 201 | 201 | 234 | 266 | 293 | 222 | 277 | 285 | 317 |
| Days Payable | 102 | 90 | 96 | 107 | 144 | 159 | 199 | 146 | 94 | 158 | 141 | 170 |
| Cash Conversion Cycle | 186 | 178 | 199 | 195 | 170 | 177 | 166 | 247 | 224 | 240 | 276 | 263 |
| Working Capital Days | 0 | 19 | 3 | −11 | 6 | 15 | 43 | 43 | 59 | 42 | 43 | 58 |
| ROCE % | 14% | 16% | 16% | 14% | 8% | 14% | 40% | 26% | 23% | 7% | 9% | 18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Laurus Labs insights
77 extracted metrics across FY06–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Concall · Sep 2026PPT
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q4 FY26 concall · Apr 2026PPT
- 30 Apr 2026
- 3 Jul 2026
- 1 Jul 2025
- 20 Jun 2024
- 22 Jun 2023
- 23 Jun 2022
- General announcements 17 Nov 2026
- General announcements 10 Nov 2026
Frequently Asked Questions about Laurus Labs
What does Laurus Labs Ltd do?
Where is Laurus Labs Ltd (LAURUSLABS) listed?
Which sector does Laurus Labs Ltd belong to?
What is the market capitalisation of Laurus Labs Ltd?
What is the PE ratio of Laurus Labs Ltd?
What is the 52-week high and low of Laurus Labs Ltd?
Does Laurus Labs Ltd pay dividends?
What is the Return on Equity (ROE) of Laurus Labs Ltd?
Company Information
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LAURUSLABS.md for Laurus Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.